Skip To Content

First gene therapy for a blinding eye disease receives FDA approval

Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the…

New Survey Initiative Engages Patients as Experts and Collaborators

Last year Fighting Blindness Canada launched its Vision Care Pathways (VCP) online tool, a set of resources and guides for people living with eye diseases. These diseases include rare genetic disorders such…

The Era of Gene Therapy – A Panel Discussion

In this panel discussion from Vision Quest Vancouver on April 27, 2019, experts from around the world introduced the new era of gene therapy and discussed what this means for the future…

Leber Congenital Amaurosis

Overview Leber congential amaurosis (LCA) is a genetic disorder that causes severe visual impairment at birth or in early childhood. It was first outlined in a paper published in 1869 by the…

X-Linked Retinoschisis

Overview X-linked retinoschisis (XLRS) is a genetic disorder that causes vision loss and begins in early childhood—the disease is sometimes called “juvenile retinoschisis” due to its early onset. As with other X-linked…

Usher Syndrome

Overview Usher syndrome is a genetic disorder characterised by the loss of both hearing and vision. It is the most common form of inherited deaf-blindness, accounting for approximately 50% of such cases…

Join the Fight!

Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.

I have read and accepted the privacy policy